Journal
JAPANESE JOURNAL OF OPHTHALMOLOGY
Volume 52, Issue 6, Pages 433-439Publisher
SPRINGER TOKYO
DOI: 10.1007/s10384-008-0580-4
Keywords
age-related macular degeneration; pegaptanib; ranibizumab; vascular endothelial growth factor; visual acuity
Categories
Funding
- Novartis Pharma AG
Ask authors/readers for more resources
Vascular endothelial growth factor (VEGF) is an important modulator of angiogenesis, and has been implicated in the pathology of a number of conditions, including age-related macular degeneration (AMD), diabetic retinopathy, and cancer. AMD is a progressive disease of the macula and the third major cause of blindness worldwide. If not treated appropriately, AMD can progress rapidly, causing legal blindness within months of the second eye becoming affected. Until recently, the treatment options for AMD have been limited, with photodynamic therapy (PDT) the mainstay treatment. Although PDT is effective at slowing disease progression, it rarely results in improved vision. Pegaptanib and ranibizumab are both anti-VEGF therapies licensed for the treatment of neovascular AMD in Europe; however, these drugs are not yet available in Japan. This article reviews the available clinical data on anti-VEGF therapies for the treatment of neovascular AMD in Europe, and considers the future of this exciting therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available